Transcatheter closure of the atrial septal defect (ASD) resulted in significant reductions in tricuspid regurgitation (TR) and improvements in right ventricular dimensions, according to a new study in JACC: Cardiovascular Interventions.

A previously unknown gene-environment interaction between maternal diabetes and transcriptional regulator Notch1 raises the risk of congenital heart disease (CHD) in children, a paper published in the Journal of Clinical Investigation: Insight states.

Low-dose colchicine therapy can favorably remodel coronary plaque following acute coronary syndrome (ACS), reducing one of the major predictors of future cardiovascular events, according to a new study in JACC: Cardiovascular Imaging.

Cardiovascular research has traditionally focused on hard clinical endpoints such as markers of disease progression, adverse events and death. But now researchers are calling for more studies that incorporate the viewpoints of patients and caregivers, both in trial design and execution and in measuring outcomes like quality of life, time off work, out-of-pocket expense and caregiver burden.

It’s well-established that cholesterol-lowering PCSK9 inhibitors (PCSK9i) are a pricey addition to any heart patient’s medication regimen, climbing to more than $14,000 per year at retail value and $5,000 in out-of-pocket costs—but they are effective.